Science driven therapeutics addresses only the diseases but does not provide cure and sometimes fails to meet the needs of patient. The pharmaceutical companies have, in recent years, started providing complementary products to improve the therapeutic value of the medicines. This is in the form of Fixed dose combination drugs (FDCs) The last couple of years have seen a trend in marketing of FDCs by pharmaceutical companies. Common focus of FDCs include anti-infectives, CNS, cardiovascular including hypertension and lipidemia, diabetes,contraceptives, HIV and respiratory. The United States Food and Drugs Administration (USFDA) have approved FDCs to treat various conditions such as hypertension, tuberculosis, AIDS and diabetes to name a few. The pharmaceutical companies developing these FDCs protect the products from their competitors with the help of patents. Patents are a form of intellectual property, which are legal and institutional mechanisms to protect creations of mind. In recent years, there are instances of patents granted for FDCs by the USFDA. This study attempts to review issue of anti-diabetic FDCs and patents.
|Number of pages||5|
|Publication status||Published - 01-01-2018|
All Science Journal Classification (ASJC) codes
- Pharmacology, Toxicology and Pharmaceutics(all)